The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
The closing price of Recursion Pharmaceuticals Inc (NASDAQ: RXRX) was $7.43 for the day, up 5.69% from the previous closing price of $7.03. In other words, the price has increased by $5.69 from its previous closing price. On the day, 13.15 million shares were traded. RXRX stock price reached its highest trading level at $7.49 during the session, while it also had its lowest trading level at $6.89.
Ratios:
Our analysis of RXRX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 4.35 and its Current Ratio is at 4.35. In the meantime, Its Debt-to-Equity ratio is 0.17 whereas as Long-Term Debt/Eq ratio is at 0.14.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Morgan Stanley on May 22, 2023, initiated with a Equal-Weight rating and assigned the stock a target price of $8.
On March 16, 2023, Needham started tracking the stock assigning a Buy rating and target price of $17.
On September 16, 2022, KeyBanc Capital Markets started tracking the stock assigning a Overweight rating and target price of $20.KeyBanc Capital Markets initiated its Overweight rating on September 16, 2022, with a $20 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jan 17 ’25 when Secora Michael bought 5,000 shares for $6.51 per share.
Secora Michael bought 15,000 shares of RXRX for $98,519 on Jan 15 ’25. On Jan 14 ’25, another insider, Secora Michael, who serves as the Former Officer of the company, bought 15,000 shares for $6.48 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RXRX now has a Market Capitalization of 2903064320 and an Enterprise Value of 1794186112. For the stock, the TTM Price-to-Sale (P/S) ratio is 44.54 while its Price-to-Book (P/B) ratio in mrq is 4.05. Its current Enterprise Value per Revenue stands at 27.525 whereas that against EBITDA is -4.927.
Stock Price History:
The Beta on a monthly basis for RXRX is 0.85, which has changed by -0.25292242 over the last 52 weeks, in comparison to a change of 0.25219524 over the same period for the S&P500. Over the past 52 weeks, RXRX has reached a high of $15.74, while it has fallen to a 52-week low of $5.60. The 50-Day Moving Average of the stock is 7.48%, while the 200-Day Moving Average is calculated to be -0.13%.
Shares Statistics:
RXRX traded an average of 13.81M shares per day over the past three months and 17794030 shares per day over the past ten days. A total of 390.76M shares are outstanding, with a floating share count of 323.81M. Insiders hold about 17.13% of the company’s shares, while institutions hold 58.02% stake in the company. Shares short for RXRX as of 1736899200 were 67857806 with a Short Ratio of 4.91, compared to 1734048000 on 67097533. Therefore, it implies a Short% of Shares Outstanding of 67857806 and a Short% of Float of 18.94.
